[Surgery and combined chemotherapy of ovarian cancer].
A) Common epithelial cancer: According to the Japanese statistics on ovarian cancer, the incidence of combined radiotherapy decreased recently from about 30% to about 5% and the combined treatment used is now mainly chemotherapy. The main drug used for combined chemotherapy is cis-DDP, especially PAC (cis-DDP, Adriamycin and Cyclophosphamide) treatment. According to our clinical experience, the survival curve of advanced cases treated with PAC in combination is better than that with former drugs. B) Endodermal sinus tumor (EST): According to our treatment results, 6 patients with EST treated in combination with radiotherapy or previous forms of chemotherapy died within 2 years. However, 4 patients with EST given combined treatment with VAC (Vincristine, Actinomycin D, Cyclophosphamide) or with PVB (cis-DDP, Vinblastine, Bleomycin) were able to survive over 2 years. The Japanese statistics show that the rate of long survival of EST patients treated in combination with VAC or with PVB is about 50%.
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000601:surgery / Q000628:therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000601:surgery / Q000628:therapy*; D011182:Postoperative Care; D013724:Teratoma / Q000601:surgery / Q000628:therapy*